BRPI0513379A - derivados de sulfonamida - Google Patents

derivados de sulfonamida

Info

Publication number
BRPI0513379A
BRPI0513379A BRPI0513379-3A BRPI0513379A BRPI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A
Authority
BR
Brazil
Prior art keywords
sulfonamide derivatives
racemates
alzheimer
disease
compounds
Prior art date
Application number
BRPI0513379-3A
Other languages
English (en)
Inventor
Guido Galley
Roland Jakob-Roetne
Eric Argirios Kitas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0513379A publication Critical patent/BRPI0513379A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

DERIVADOS DE SULFONAMIDA. A invenção refere-se a Compostos da fórmula geral (I), em que R¬ 1¬-R¬ 5¬ e R¬ 2¬-R¬ 4¬ são como descrito nas reivindicações e a sais de adição de ácido farmaceuticamente adequados, enantiómeros puros óticos, racematos ou misturas diastereoméricas destes para o tratamento de doença de Alzheimer ou cânceres comuns.
BRPI0513379-3A 2004-07-13 2005-07-06 derivados de sulfonamida BRPI0513379A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103339 2004-07-13
PCT/EP2005/007268 WO2006005486A1 (en) 2004-07-13 2005-07-06 Sulfonamide derivatives

Publications (1)

Publication Number Publication Date
BRPI0513379A true BRPI0513379A (pt) 2008-05-06

Family

ID=34971295

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513379-3A BRPI0513379A (pt) 2004-07-13 2005-07-06 derivados de sulfonamida

Country Status (11)

Country Link
US (1) US7253158B2 (pt)
EP (1) EP1768960A1 (pt)
JP (1) JP4845883B2 (pt)
KR (1) KR100880972B1 (pt)
CN (2) CN101747324A (pt)
AU (1) AU2005261932B2 (pt)
BR (1) BRPI0513379A (pt)
CA (1) CA2573372A1 (pt)
MX (1) MX2007000468A (pt)
RU (1) RU2378258C2 (pt)
WO (1) WO2006005486A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
WO2006078753A1 (en) * 2005-01-18 2006-07-27 Elan Pharmaceuticals, Inc. N-substituted heterocyclic sulfonamides
DE602006019103D1 (de) * 2005-08-12 2011-02-03 Hoffmann La Roche Fluorsubstituierte 2-oxo-azepan-derivate
WO2009071448A1 (en) * 2007-12-05 2009-06-11 Basf Se Pyridylmethyl-sulfonamide compounds
US8457989B2 (en) * 2009-01-09 2013-06-04 Cerner Innovation, Inc. Direct reporting of adverse events
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
GB201009603D0 (en) 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
WO2012014127A1 (en) * 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CN102718711A (zh) * 2011-03-30 2012-10-10 北京德众万全医药科技有限公司 一种制备(R)-α-氨基己内酰胺盐酸盐的新方法
CN102911118B (zh) * 2012-11-09 2014-04-09 天津商业大学 一类苯并氮杂卓类衍生物及其制备方法和用途
CN103073498A (zh) * 2012-12-21 2013-05-01 北京万全德众医药生物技术有限公司 (R)-α-氨基己内酰胺的制备新方法
TW201609656A (zh) 2013-09-26 2016-03-16 美涅莫辛製藥公司 Ｎｒ２ａ之ｎ-芳基甲基磺醯胺負向調節劑
ES2821010T3 (es) 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações
CN109320456A (zh) * 2018-11-16 2019-02-12 天津商业大学 新晶型的抗肿瘤化合物及其制备方法和含其的组合物
CN117447298A (zh) * 2023-08-29 2024-01-26 上海泰坦科技股份有限公司 一种卤代甲基二氟甲基苯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593888A (en) * 1977-12-22 1981-07-22 Wyeth John & Brother Ltd Hexahydroazepine piperidine and pyrrolidine derivatives
US6107291A (en) 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
EP1268434A1 (en) * 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
JP2006520396A (ja) * 2003-03-14 2006-09-07 アストラゼネカ・アクチエボラーグ 新規なラクタム及びその使用
EP1680406A1 (en) * 2003-10-29 2006-07-19 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides

Also Published As

Publication number Publication date
AU2005261932B2 (en) 2011-10-13
EP1768960A1 (en) 2007-04-04
JP4845883B2 (ja) 2011-12-28
RU2007100229A (ru) 2008-08-20
MX2007000468A (es) 2007-03-08
US20060014945A1 (en) 2006-01-19
CN101035765A (zh) 2007-09-12
WO2006005486A1 (en) 2006-01-19
AU2005261932A1 (en) 2006-01-19
US7253158B2 (en) 2007-08-07
CA2573372A1 (en) 2006-01-19
JP2008505948A (ja) 2008-02-28
KR20070026799A (ko) 2007-03-08
RU2378258C2 (ru) 2010-01-10
CN101747324A (zh) 2010-06-23
KR100880972B1 (ko) 2009-02-03
CN101035765B (zh) 2010-10-13

Similar Documents

Publication Publication Date Title
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
BR0214386A (pt) Método para identificação de enzimas de objetivação a tumor
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0519243A2 (pt) mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
EA200901373A1 (ru) Аминогетероциклические соединения
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
BR0210384A (pt) Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
NO20075111L (no) Farmasoytisk sammensetning
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
EA200401114A3 (ru) Замещённые гидроксиэтиламины
SE0401970D0 (sv) Novel compounds
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
BRPI0511874A (pt) derivados da pirrolopiridina
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.